Shown here are some of the recent outstanding publications which highlight significant advances made by researchers in our institute.
The Lancet Child & Adolescent Health. February 12, 2020. Aneel Bhangu (RIFT Study Group on behalf of the West Midlands Research Collaborative). Appendicitis risk prediction models in children presenting with right iliac fossa pain (RIFT study): a prospective, multicentre validation study. (https://www.birmingham.ac.uk/university/colleges/mds/news/2020/02/childhood-appendicitis-improvements.aspx)
Lancet 395:417-426 (2020). Aneel Bhangu (Reinforcement of Closure of Stoma Site Collaborative and West Midlands Research Collaborative). Prophylactic biological mesh reinforcement versus standard closure of stoma site (ROCSS): a multicentre, randomised controlled trial.
Nature 571:521-527 (2019). Daza-Martin M, et al. Isomerization of BRCA1-BARD1 promotes replication fork protection. DOI: 10.1038/s41586-019-1363-4
Nature Genetics 51:151-162 (2019). Assi SA, et al. Subtype-specific regulatory network rewiring in acute myeloid leukemia.
Cell Reports 25: 2061–2069 (2018). Bowry A, et al. BET inhibition induces HEXIM1- and RAD51-dependent conflicts between transcription and replication.
Cancer Cell 34:626-642 e628 (2018). Martinez-Soria N, et al. The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation.
Cancer Cell 34:674-689 e678 (2018). de Boer B, et al. Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones.
Molecular Cell 71:25-41 e26 (2018). Higgs MR, et al. Histone Methylation by SETD1A Protects Nascent DNA through the Nucleosome Chaperone Activity of FANCD2.
Nature Communications 9:2442 (2018). Campbell KR, Yau C Uncovering pseudotemporal trajectories with covariates from single cell and bulk expression data.
Nature Communications 9:2704 (2018). Gauvrit S, et al. HHEX is a transcriptional regulator of the VEGFC/FLT4/PROX1 signaling axis during vascular development.
Nature Communications 9:746 (2018). Ronson GE, et al. PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation.
Cell Reports 24:1496-1511 e1498 (2018). Ward C, et al. Fine-Tuning Mybl2 Is Required for Proper Mesenchymal-to-Epithelial Transition during Somatic Reprogramming.
Nature Communications 9:229 (2018). Uckelmann et al. USP48 restrains resection by site-specific cleavage of the BRCA1 ubiquitin mark from H2A.
N Engl J Med 377:338-351 (2017). James ND, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Cell 168: 843 (2017). Williamson et al. UV Irradiation Induces a Non-coding RNA that Functionally Opposes the Protein Encoded by the Same Gene.
Cell Reports 21:3498-3513 (2017). Chiang K, et al. PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression.
Cell Reports 19: 1654 (2017). Loke et al. RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML.
Nature Cell Biology (2017) doi: 10.1038/ncb3500 Sonneville R et al. CUL-2LRR-1 and UBXN-3 drive replisome disassembly during DNA replication termination and mitosis.
Molecular Cell 65:900-916 (2017). Clarke TL et al.PRMT5-dependent methylation of the TIP60 coactivator RUVBL1 is a key regulator of homologous recombination.
Nature Genetics 49:537-549 (2017). Reynolds JJ et al. DONSON encodes a novel replication fork protection factor mutated in microcephalic dwarfism.
Lancet 387:1163-1177 (2016). James ND, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Cancer Cell 30:578 (2016). Bardella et al. Expression of Idh1R132H in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early Gliomagenesis.
Nature Genetics 48:667 (2016). Cheng et al. Five endometrial cancer risk loci identified through genome-wide association analysis.
Nature Communications 7:13087 (2016). Kotsantis P, et al. Increased global transcription activity as a mechanism of replication stress in cancer.
Nature Structural and Molecular Biology 23:647-655 (2016). Densham R, et al. The BRCA1:BARD1 Ubiquitin ligase activity counters chromatin barriers to DNA resection.
New England Journal of Medicine 374:1444-1454 (2016). Mehanna H, et al. PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer.
Nature Genetics 48:36-43 (2016). Harley ME, et al. TRAIP promotes DNA damage response during genome replication and is mutated in primordial dwarfism.
EMBO J 35:515-535 (2016). Bevington SL, et al. Inducible chromatin priming is associated with the establishment of immunological memory in T cells.
Developmental Cell 36:572-587 (2016). Goode et al. Dynamic Gene Regulatory Networks Drive Hematopoietic Specification and Differentiation.
Molecular Cell 59:462-477 (2015). Higgs MR, et al. BOD1L Is Required to Suppress Deleterious Resection of Stressed Replication Forks.
Nature Communications 6:7203 (2015). Regha K, et al. Developmental-stage-dependent transcriptional response to leukaemic oncogene expression.
Cell Reports 12:821-836 (2015). Cauchy P, et al. Chronic FLT3-ITD Signaling in Acute Myeloid Leukemia Is Connected to a Specific Chromatin Signature.
Lancet 386:9990 (2015). Kehoe et al.Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
Nature Medicine 21:62 (2014). Davis et al. Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche.
Cell 157:1037-1049 (2014). Saponaro M, et al. RECQL5 controls transcript elongation and suppresses genome instability associated with transcription stress.
Cell Reports 8: 983 (2014). Lewis et al. A Polymorphic Enhancer near GREM1 Influences Bowel Cancer Risk through Differential CDX2 and TCF7L2 Binding.
Science 346:477-481 (2014). Moreno SP, et al. Polyubiquitylation drives replisome disassembly at the termination of DNA replication.
Nature Communications 5:3756 (2014). Cazier JB, et al. Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.
Cell Reports 8:1974-1988 (2014). Ptasinska A, et al. Identification of a Dynamic Core Transcriptional Network in t(8;21) AML that Regulates Differentiation Block and Self-Renewal.
Molecular Cell 53:645-654 (2014). Feng T, et al. Optimal translational termination requires C4 lysyl hydroxylation of eRF1.
Nature 507:381-385 (2014). Haberle V, et al. Two independent transcription initiation codes overlap on vertebrate core promoters.
Nature Genetics 45:136 (2013). Palles et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.
Cell Reports 5:1302-1315 (2013). Sarkar S, et al. Impaired autophagy in the lipid-storage disorder Niemann-Pick type C1 disease.
Genome Research 23:1938-1950 (2013). Nepal C, et al. Dynamic regulation of the transcription initiation landscape at single nucleotide resolution during vertebrate embryogenesis.
EMBO Reports 14:975-983 (2013). Garvin AJ, et al. The deSUMOylase SENP7 promotes chromatin relaxation for homologous recombination DNA repair.
Lancet Oncology 13:1152-1160 (2012). Foxtrot Collaborative Group/Morton D. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.
Molecular Cell 45:505-516 (2012). Polo SE, et al. Regulation of DNA-end resection by hnRNPU-like proteins promotes DNA double-strand break signaling and repair.
Cell Reports 2:270-282 (2012). Radulescu S, et al. Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo.
EMBO J 31:3918-3934 (2012). Butler LR, et al. The proteasomal de-ubiquitinating enzyme POH1 promotes the double-strand DNA break response.
EMBO J 31:4318-4333 (2012). Lichtinger M, et al. RUNX1 reshapes the epigenetic landscape at the onset of haematopoiesis.
Nature Chemical Biology 8:960-962 (2012). Ge W, et al. Oxygenase-catalyzed ribosome hydroxylation occurs in prokaryotes and humans.
Journal of Clinical Oncology 36: 4524 (2012). Skowronska et al. Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial.
Journal of Clinical Oncology 36: 4477 (2012). Bartlett et al. Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study.
Lancet 377:321-331 (2011). van de Velde CJ, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
Cancer Cell 20:797-809 (2011). Drost R, et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.
Molecular Cell 43:19-32 (2011). Sarkar S, et al. Complex inhibitory effects of nitric oxide on autophagy.
Nature Genetics 43:1169-1170 (2011). Lin H, et al. Relative overexpression of X-linked genes in mouse embryonic stem cells is consistent with Ohno's hypothesis.
PNAS 107:10799-10803 (2010). Ludwig C, et al. Quantum rotor induced hyperpolarization.
Nature Cell Biology 12:963-972 (2010). Davies CC, et al. Identification of a co-activator that links growth factor signalling to c-Jun/AP-1 activation.
Molecular Cell 37:492-502 (2010). Petermann E, et al. Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair.
Proc Natl Acad Sci U S A 107:16090-16095 (2010). Petermann E, et al. Chk1 promotes replication fork progression by controlling replication initiation.
Lancet Neurology 9:581-591 (2010). Williams A, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial.
PNAS 107:12251-12256 (2010). Blackford AN, et al. Adenovirus 12 E4orf6 inhibits ATR activation by promoting TOPBP1 degradation.